Online Ketamine Therapy

Important: ThriveTalk does not provide ketamine therapy

ThriveTalk does not provide ketamine therapy. We do not prescribe, supply, or administer ketamine in any form. Our network is made up of independently licensed talk-therapy clinicians (Licensed Marriage and Family Therapists, Licensed Clinical Social Workers, Licensed Professional Counselors, and psychologists) who deliver evidence-based psychotherapy by secure video, phone, or text. Ketamine is a Schedule III controlled substance under U.S. federal law and can only be prescribed by a qualified medical prescriber: a psychiatrist, family physician, nurse practitioner, or physician assistant operating within their scope of practice.

If you are looking for ketamine treatment, you need a medical prescriber, not a talk therapist. This page exists so people researching online ketamine therapy can find a clear, non-promotional explanation of how those services work and what to consider. It is not a referral, endorsement, or service offering from ThriveTalk.

What "online ketamine therapy" actually means

"Online ketamine therapy" is a marketing umbrella for several distinct service models. Knowing which model a clinic is offering matters, because the safety profile, the evidence base, and the regulatory posture are very different across them.

• At-home oral ketamine via telehealth. A patient completes a video intake with a prescriber, receives compounded sublingual lozenges or troches by mail, and self-administers them at home, sometimes with a support person on a video call. This is the model the FDA singled out in its October 2023 compounding risk alert.
• In-clinic intravenous (IV) or intramuscular (IM) ketamine with a telehealth intake and follow-up. The patient is evaluated remotely, but the actual ketamine dose is delivered in a medical setting with vital-signs monitoring.
• FDA-approved esketamine (Spravato) under a REMS program. Esketamine is a nasal-spray form of ketamine, FDA-approved in 2019 for treatment-resistant depression. It can only be administered in a certified clinic, and the patient must be observed for at least two hours after each dose. There is no at-home version.
• Ketamine-assisted psychotherapy (KAP). A separately licensed therapist supports preparation and integration sessions around ketamine doses given by a medical prescriber. The therapist is not the prescriber.

What the FDA has and hasn't approved

This is the single most-misrepresented part of the online-ketamine market, so it's worth being precise. Esketamine (Spravato) is the only ketamine-derived product the FDA has approved for any psychiatric indication: treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder who have acute suicidal ideation. Spravato is delivered as a nasal spray in a certified clinic under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-person observation after each dose.

Racemic ketamine, the form most online clinics use, is FDA-approved as an anesthetic, but its use for depression, anxiety, PTSD, or any other psychiatric condition is off-label. That doesn't make it illegal for a licensed prescriber to prescribe. It does mean the FDA has not reviewed it for that purpose, and clinics offering it cannot legally claim it is FDA-approved for mental-health care.

On October 10, 2023, the FDA published a compounding risk alert specifically warning patients and prescribers about compounded ketamine products, including oral formulations, marketed through telemedicine platforms for psychiatric use. The alert described an April 2023 adverse event report: a patient who took compounded oral ketamine at home for PTSD developed respiratory depression, with a ketamine blood level roughly twice what is typically reached during anesthesia. The FDA also stressed that compounded ketamine has never been evaluated by the agency for safety, effectiveness, or quality, and is not covered by any REMS monitoring requirements. If a service is mailing you ketamine lozenges, that is the exact product this alert is about.

What the evidence actually shows

The strongest evidence base is for IV ketamine and intranasal esketamine in adults with treatment-resistant depression, generally defined as a major depressive episode that has not responded to two or more adequate trials of standard antidepressants. The National Institute of Mental Health summarizes the research this way: a single dose of IV ketamine can produce a rapid antidepressant effect within hours in some patients, and esketamine has shown similar effects in the randomized trials supporting its FDA approval.

Two important caveats. First, the effect is often short-lived. Many patients relapse within days to weeks without repeated dosing, which is why Spravato's label calls for an induction phase followed by ongoing maintenance treatment. Second, long-term safety data are limited. Most randomized trials run for weeks, not years, so the long-run effects of repeated ketamine exposure on cognition, urinary tract health, and dependence risk are not well characterized.

Evidence for at-home oral ketamine for psychiatric use is substantially weaker than the evidence for clinic-administered IV ketamine or esketamine. The bioavailability is different, dosing is harder to control, and the studies that exist are mostly small open-label series from the same clinics that sell the service.

Risks and side effects

Ketamine is a powerful dissociative anesthetic. Even at the lower doses used in psychiatric care, the risk profile is real and worth understanding before considering treatment.

• Dissociation and perceptual changes during and shortly after dosing: feeling detached from your body, your surroundings, or time. This is expected but can be distressing and, in unsupervised settings, can lead to falls or other injuries.
• Cardiovascular effects. Ketamine reliably raises blood pressure and heart rate. The Spravato label requires blood-pressure monitoring before and after each dose for this reason. People with uncontrolled hypertension, recent cardiovascular events, or vascular disease are generally not candidates.
• Respiratory depression (dangerously slowed breathing) at high blood levels, the adverse event at the center of the FDA's 2023 alert on at-home compounded ketamine.
• Bladder and urinary-tract toxicity with chronic or high-dose use (ketamine cystitis), well documented in long-term recreational users and a concern as long-term medical use grows.
• Abuse and dependence. Ketamine is a Schedule III controlled substance under U.S. federal law (per the Drug Enforcement Administration), reflecting recognized potential for misuse. Risk is higher when ketamine is sent home for unsupervised use.
• Drug interactions with benzodiazepines, opioids, stimulants, and certain blood-pressure medications. A prescriber needs a full medication list before treatment.
• Risks of unsupervised at-home dosing specifically: no one is monitoring blood pressure, no one is screening for dissociation severity, and no one can intervene if something goes wrong. This is the central concern in the FDA's alert.

Who is and isn't a candidate

Most legitimate ketamine providers limit treatment to adults with treatment-resistant depression (typically defined as failure to respond to two or more adequate antidepressant trials), and many extend to certain cases of severe anxiety, PTSD, or acute suicidality after careful evaluation. Using ketamine first-line, before trying standard lower-risk treatments, is not supported by the evidence and is not consistent with FDA labeling for esketamine.

Ketamine is generally not appropriate for people with active or recent substance use disorders (especially involving dissociatives or stimulants), uncontrolled hypertension or recent cardiovascular events, a history of psychosis or schizophrenia spectrum disorders, pregnancy, or severe untreated bladder or urinary-tract disease. A responsible prescriber will screen for all of these before offering treatment.

The temporary rule that makes at-home prescribing possible

There is one more piece most clinic websites skip. Under the federal Ryan Haight Act, a prescriber normally must conduct at least one in-person medical evaluation before prescribing any controlled substance, ketamine included. Telehealth-only ketamine prescribing is possible today only because the DEA and the Department of Health and Human Services adopted temporary telemedicine flexibilities during COVID-19 and have kept renewing them a year at a time. The fourth extension runs through December 31, 2026, while the DEA works on permanent telemedicine prescribing rules.

That has a practical consequence: the entire at-home ketamine model rests on a rule with an expiration date. If you are considering a telehealth ketamine program, ask the clinic what happens to your care if the flexibilities lapse or the final rules require an in-person exam, and whether it has in-person clinical partners near you.

If you're looking for support today

If you're researching ketamine because standard antidepressants haven't worked for you, the right next step is usually a conversation with a psychiatrist, not a direct sign-up for an online ketamine clinic. A psychiatrist can review the trials you've already had, consider next-line options including esketamine in a REMS-certified clinic, and refer you to a clinic-based ketamine program if appropriate. The American Psychiatric Association and Psychology Today both maintain searchable directories of psychiatrists by location.

If you're looking for talk-therapy support with depression, anxiety, grief, trauma, or relationship concerns, that is what ThriveTalk does. We match adults with independently licensed clinicians who deliver evidence-based psychotherapy by secure video, phone, or text.

If you are in crisis or thinking about suicide, please contact the 988 Suicide & Crisis Lifeline (call or text 988 in the United States) right now, or see our crisis resources page for additional immediate-help options.